Vipadenant (, ; developmental code name BIIB014 and others) is an adenosine A2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed. It is taken orally. The drug was first described in the scientific literature by 2006.Lightowler, S., Knight, A. R., & Upton, R. (2006). Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders. Boston, USA. https://scholar.google.com/scholar?cluster=5861921750099200903 It was under development by Vernalis, Biogen, and Juno Therapeutics. Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.
See also Adenosine receptor antagonist List of investigational Parkinson's disease drugs
References